Find what’s driving
Advanced cancer patients per year in the United States without an actionable driver
Driver-negative patients have alterations in a gene targeted by an FDA-approved therapy
Driver-negative solid tumor patients in the Aventa clinical study
Reveal druggable targets
Fusions in genes like ALK, ROS, RET, and NTRK are targeted by fusion-inhibiting therapies. The Aventa FusionPlus test doubles the diagnostic yield of these targetable fusions, providing better treatment options for these patients.
Resolve diagnostic dilemmas
Translocations are the basis for definitive diagnosis in sarcomas, salivary gland cancers, brain cancers, and others. The Aventa FusionPlus test identifies translocations in the genes most commonly used for tumor diagnosis.
361 Genes in the Aventa FusionPlus Test
Aventa is committed to ensuring access for all eligible patients. If insurance approves test coverage, patients are only responsible for their copay, coinsurance, and deductible. Their out-of-pocket cost may be further reduced if they are eligible for financial assistance through the Aventa Assist program. Please contact us if you have any questions.
Frequently Asked Questions
Who should receive Aventa testing?
What sample type is required?
Is a new biopsy or surgical resection required for Aventa testing?
Is Aventa testing reimbursed by insurance?
How do I order the Aventa testing service for my patient?
What information is provided by the Aventa testing service?
Thank you for sharing this with us!
Someone from our team will reach out to you soon.